A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - Respiratory - NCCTG-N0426
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426 Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2010 Manuscript - Primary - Primary - Respiratory - N0426
A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer. Adjei, A. A. , Molina, J. R. , Hillman, S. L. , Luyun, R. F. ... - - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - Respiratory - NCCTG-N0326
Correlation between polymorphisms in the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer (NSCLC): An NCCTG N0026 based study. Abstract 198. Adjei, A. , Salavaggione, O. , Mandrekar, S. , Dy, G. ... - NCI TSM - - 2009 Abstract - Secondary-not-in-original - Primary - Respiratory - NCCTG-N0026
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. Adjei, Araba A , Salavaggione, Oreste E , Mandrekar, Sumithra J ... - - J Thorac Oncol - 2010 Manuscript - Secondary-not-in-original - Primary - Respiratory - N0026
Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer Bryce, Alan H. , Mattar, Bassam , Hillman, Shauna L. , Adjei, Alex A. ... - - Am. J. Clin. Oncol. - 2010 Manuscript - Primary - Primary - Respiratory - NCCTG-0027
A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102. Cathcart-Rake, Elizabeth , Novotny, Paul , Leon-Ferre, Roberto ... - - Support Care Cancer - 2020 Manuscript - Primary - Primary - Symptom Inter - A221102
Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial. Dilts, D. M. , Adjei, A. A. , Mandrekar, S. J. , Buckner, J. C. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original - Comprehensive - Respiratory - NCCTG-N0723
A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). Dy, G. K. , Mandrekar, S. J. , Nelson, G. D. , Ross, H. J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Respiratory - NCCTG-N0528
N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2) Dy, G. K. , Molina, J. , Qi, Y. , Ansari, R. H. , Thomas, S. ... - - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Respiratory - NCCTG-N0821
A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N03261 Dy, Grace K. , Hillman, Shauna L. , Rowland, Kendrith M. ... - - Cancer - 2010 Manuscript - Primary - Primary - Respiratory - N0326
A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without Cediranib as First-Line Therapy in Advanced Non-Small Cell Lung Cancer: North Central Cancer Treatment Group Study N0528 Dy, Grace K. , Mandrekar, Sumithra J. , Nelson, Garth D. ... - - J Thorac Oncol - 2013 Manuscript - Primary - Primary - Respiratory - N0528
NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status Dy, Grace K. , Molina, Julian R. , Qi, Yingwei , Ansari, Rafat ... - - J Thorac Oncol - 2014 Manuscript - Primary - Primary - Respiratory - NCCTG-N0821
Age, Gender, Performance Status and Stage Outperformed Stage alone in Predicting Overall Survival (OS) in Patients with Small Cell Lung Cancer: A Pooled Analysis of 1623 patients from the North Central Cancer Treatment Group. Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary - Primary - Respiratory - N0424
Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation. Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - Respiratory - N0424
Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. Foster, N. R. , Qi, Y. , Krook, J. E. , Kugler, J. W. , Kuross, S. A. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Comprehensive - Respiratory - N0424
Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. Foster, N. R. , Qi, Y. , Shi, Q. , Krook, J. E. , Kugler, J. W. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Respiratory - NCCTG-N0424
Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis Foster, N. R. , Renfro, L. A. , Schild, S. E. , Redman, M. W. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Meta-Analysis - Respiratory - Comprehensive , CALGB-9033 , CALGB-9732 , CALGB-30103 , NCCTG-862051 , NCCTG-892051 , NCCTG-932053 , ECOG-1500 , ECOG-7593 , JCOG-9511 , NCIC-BR4 , NCIC-BR8 , SWOG-S0124
Prognostic factors differ by tumor stage for Small Cell Lung Cancer: A Pooled Analysis of North Central Cancer Treatment Group (NCCTG) Trials Foster, Nathan R. , Mandrekar, Sumithra J. , Schild, Steven E. ... - - Cancer - 2009 Manuscript - Secondary - Primary - Respiratory - N0424
Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials Foster, Nathan R. , Qi, Yingwei , Shi, Qian , Krook, James E. ... - - Cancer - 2011 Manuscript - Primary - Primary - Respiratory - N0424
Multi-Trial Evaluation of Progression-Free Survival (PFS) as a Surrogate Endpoint for Overall Survival (OS) in First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Foster, Nathan R. , Renfro, Lindsay A. , Schild, Steven E. ... - - J Thorac Oncol - 2015 Manuscript - Secondary-not-in-original - Meta-Analysis - Respiratory - CALGB-30103 , N0424 , NCCTG-932053
A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422) Jatoi, A. , Schild, S. E. , Foster, N. , Henning, G. T. ... - - Ann Oncol - 2010 Manuscript - Primary - Primary - Respiratory - NCCTG-N0422
Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study Jett, J. R. , Bernath, A. Jr , Foster, N. , Molina, J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - Respiratory - NCCTG-N0423
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Johnson, Elizabeth A , Marks, Randolph S , Mandrekar, Sumithra J ... - - Lung Cancer - 2008 Manuscript - Primary - Primary - Respiratory - NCCTG-972451
Are actual tumor measurements or categorical tumor response status better at predicting overall survival in cancer clinical trials? Mandrekar, M. D. , Hillman, S. L. , Campbell, M. E. , Hobbs, B. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original - Comprehensive - GI - N9741
Comparison of progression-free survival (PFS) with best or confirmed response (BR, CR) as an endpoint for overall survival (OS) in advanced non small cell lung cancer (A-NSCLC): A North Central Cancer Treatment Group (NCCTG) investigation Mandrekar, S. J. , Hillman, S. L. , Ziegler, K. L. Allen ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - Respiratory - N0424
Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: a joint North Center Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation Mandrekar, S. J. , Qi, Y. , Allen-Ziegler, K. , Hillman, S. L. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - Respiratory - N0424
Impact of the Algorithm for Declaring Exact Progression Data on Progression-Free Survival Estimates in Advanced Lung Cancer Mandrekar, S. , Hillman, S. , Jatoi, A. , Jett, J. , Schild, S. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - Respiratory - N0424
Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer Mandrekar, Sumithra J. , Foster, Nathan R. , Qi, Yingwei ... - ASCO - J. Clin. Oncol. - 2012 Abstract - No-Endpoint - Comprehensive - Respiratory - N0424
A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study Molina, J. R. , Dy, G. K. , Foster, N. R. , Ziegler, Allen ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary - Primary - Respiratory - N0626
A randomized double-blinded phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG N0923 (Alliance) Study Molina, J. R. , Mandrekar, S. J. , Dy, G. , Aubry, M. C. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary - Primary - Respiratory - N0923
A phase II study of the VEGFR inhibitor pazopanib (P) in patients with newly diagnosed or relapsed malignant pleural mesothelioma (MPM): an NCCTG study Molina, J. R. , Mandrekar, S. J. , Ziegler, K. L. Allen ... - - J Thorac Oncol - 2009 Abstract - Primary - Primary - Respiratory - NCCTG-N0623
NCCTG Phase II Trial (N0621) of the SRC inhibitor AZD0530 after 4 cycles of cytoreductive chemotherapy for patients with Extensive Stage Small Cell Lung Cancer (ED-SCLC) Molina, Julian R. , Foster, Nathan R. , Nelson, Garth D. ... - IASLC (WCLC) - J Thorac Oncol - 2009 Abstract - Primary - Primary - Respiratory - N0621
A phase II trial of the Src-kinase inhibitor saracatinib after 4 cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621 Molina, Julian R. , Foster, Nathan R. , Reungwetwattana, Thanyanan ... - - Lung Cancer - 2014 Manuscript - Primary - Primary - Respiratory - N0621
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. Okuno, Scott H , Delaune, Robert , Sloan, Jeff A , Foster, Nathan R ... - - Cancer - 2008 Manuscript - Primary - Primary - Respiratory - N0021
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance) Parikh, Kaushal , Mandrekar, Sumithra J. , Allen‐Ziegler, Katie ... - - Oncologist - 2020 Manuscript - Primary - Primary - Respiratory - NCCTG-N0623
Incidence of bleeding and thrombosis among elderly patients undergoing systemic chemotherapy in advanced non-small cell lung cancer: An analysis of North Central Cancer Treatment Group trials Qi, Y. , Dy, G. K. , Nelson, G. D. , Schild, S. E. , Mandrekar, S. J. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - Respiratory - N0424
Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer Qi, Y. , Ziegler, K. L. Allen , Hillman, S. L. , Redman, M. W. ... - - Cancer - 2012 Manuscript - Secondary-not-in-original - Comprehensive - Respiratory - N0022 , N0026 , N0222 , N0323 , N0326 , N0426 , N0528 , N0626 , N0821 , N9921
Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer Qi, Yingwei , Schild, Steven E. , Mandrekar, Sumithra J. ... - - J Thorac Oncol - 2009 Manuscript - Secondary - Primary - Respiratory - N0424
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. Reungwetwattana, Thanyanan , Molina, Julian R ... - - J Thorac Oncol - 2012 Manuscript - Primary - Primary - Respiratory - N0323
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. Schenk, Erin L , Mandrekar, Sumithra J , Dy, Grace K ... - - J Thorac Oncol - 2020 Manuscript - Primary - Primary - Respiratory - N0923
Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis Schild, S. E. , Foster, N. R. , Meyers, J. P. , Ross, H. J. ... - - Ann. Oncol. - 2012 Manuscript - Secondary-not-in-original - Comprehensive - Respiratory - NCCTG-86-20-51 , NCCTG-89-20-51 , NCCTG-89-20-52 , NCCTG-95-20-53
N0321: A phase II study of bortezomib, paclitaxel, carboplatin, and radiotherapy for locally advanced non-small cell lung cancer Schild, S. E. , Molina, J. R. , Dy, G. K. , Rowland, K. M., Jr ... - - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Respiratory - NCCTG-N0321
Baseline quality of life (QOL) as a prognostic factor for overall survival (OS) in patients (Pts) with advanced stage non-small cell lung cancer (A-NSCLC): An analysis of NCCTG studies. Schild, S. E. , Qi, Y. , Tan, A. D. , Mandrekar, S. J. , Adjei, A. A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - Respiratory - NCCTG-N0424
Prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC): Findings from a North Central Cancer Treatment Group (NCCTG) pooled analysis. Schild, S. , Foster, N. , Meyers, J. , Olivier, K. , Ross, H. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Comprehensive - Respiratory - NCCTG-89-20-51 , NCCTG-89-20-52 , NCCTG-892052 , NCCTG-95-20-53
Survival of patients (pts) treated with high-dose radiotherapy (RT) and concurrent chemotherapy for unresectable non-small cell lung cancer (NSCLC). Schild, S. , Graham, D. , Hillman, S. , Vora, S. , Yolanda, G. ... - - J. Clin. Oncol. - 2009 Abstract - Primary - Primary - Respiratory - NCCTG-N0028
Long-term Survival of Patients (pts) Treated with High-dose Radiotherapy(rt) and Concurrent Chemotherapy for Unresectable Non-small Cell Lung Cancer (nsclc) Schild, S. , Hillman, S. , Graham, D. , Vora, S. , Garces, Y. ... - MSTO - J Thorac Oncol - 2012 Abstract - Primary - Long-Term-Followup - Respiratory - NCCTG-N0028
The value of combined modality therapy in elderly patients with stage III non-small cell lung cancer (NSCLC) Schild, S. , Mandrekar, S. , Jatoi, A. , Mcginnis, W. , Stella, P. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original - Comprehensive - Respiratory - NCCTG-94-24-52 , NCCTG-90-24-51
N0321: A Phase I Study of bortezomib, Paclitaxel, Carboplatin (CBDCA) & Radiotherapy (RT) for Locally-Advanced Non-Small Cell Lung Cancer (NSCLC) Schild, S. , Molina, J. , Dy, G. , Rowland, K., Jr , Sarkaria, J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Preliminary - Respiratory - NCCTG-N0321
Long-terms results of a trial of concurrent chemotherapy and escalating doses of radiation for unresectable non–small cell lung cancer: NCCTG N0028 (Alliance) Schild, Steven E. , Hillman, Shauna L. , Tan, Angelina D. ... - - J Thorac Oncol - 2017 Manuscript - Primary - Long-Term-Followup - Respiratory - NCCTG-N0028
Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). Schild, Steven E , Bonner, James A , Hillman, Shauna ... - - J. Clin. Oncol. - 2007 Manuscript - Primary - Primary - Respiratory - NCCTG-95-20-53
The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Schild, Steven E , Mandrekar, Sumithra J , Jatoi, Aminah ... - - Cancer - 2007 Manuscript - Secondary-not-in-original - Meta-Analysis - Respiratory - NCCTG-90-24-51 , NCCTG-94-24-52
Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Schild, Steven E , McGinnis, William L , Graham, David ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2006 Manuscript - Primary - Primary - Respiratory - NCCTG-N0028
Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials Wang, Xiaofei , Wang, Xiaoyi , Hodgson, Lydia , George, Stephen L. ... - - Oncologist - 2017 Manuscript - Secondary-not-in-original - Primary - Respiratory - C8435 , C8638 , C8833 , C8933 , C9031 , CALGB-30101 , CALGB-30107 , CALGB-30307 , CALGB-30601 , CALGB-39807 , CALGB-9131 , CALGB-9234 , CALGB-9530 , CALGB-9631 , CALGB-9733 , N0021 , NCCTG-N0623
A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321 Zhao, Yujie , Foster, Nathan R. , Meyers, Jeffrey P. ... - - J Thorac Oncol - 2015 Manuscript - Primary - Primary - Respiratory - NCCTG-N0321
